SATELLOS BIOSCIENCE INC (MSLE) Fundamental Analysis & Valuation

NASDAQ:MSLE • CA80401L8033

Current stock price

7.17 USD
-0.19 (-2.58%)
At close:
7.17 USD
0 (0%)
After Hours:

This MSLE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MSLE Profitability Analysis

1.1 Basic Checks

  • MSLE had negative earnings in the past year.
  • MSLE had a negative operating cash flow in the past year.
  • MSLE had negative earnings in each of the past 5 years.
  • MSLE had a negative operating cash flow in each of the past 5 years.
MSLE Yearly Net Income VS EBIT VS OCF VS FCFMSLE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • MSLE has a Return On Assets of -58.46%. This is comparable to the rest of the industry: MSLE outperforms 41.86% of its industry peers.
  • MSLE has a Return On Equity (-64.49%) which is in line with its industry peers.
Industry RankSector Rank
ROA -58.46%
ROE -64.49%
ROIC N/A
ROA(3y)-88.56%
ROA(5y)-132.25%
ROE(3y)-143.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MSLE Yearly ROA, ROE, ROICMSLE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MSLE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MSLE Yearly Profit, Operating, Gross MarginsMSLE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MSLE Health Analysis

2.1 Basic Checks

  • MSLE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MSLE Yearly Shares OutstandingMSLE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MSLE Yearly Total Debt VS Total AssetsMSLE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 22.74 indicates that MSLE is not in any danger for bankruptcy at the moment.
  • MSLE's Altman-Z score of 22.74 is amongst the best of the industry. MSLE outperforms 89.34% of its industry peers.
  • MSLE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.74
ROIC/WACCN/A
WACCN/A
MSLE Yearly LT Debt VS Equity VS FCFMSLE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 10.70 indicates that MSLE has no problem at all paying its short term obligations.
  • MSLE's Current ratio of 10.70 is amongst the best of the industry. MSLE outperforms 82.17% of its industry peers.
  • MSLE has a Quick Ratio of 10.70. This indicates that MSLE is financially healthy and has no problem in meeting its short term obligations.
  • MSLE's Quick ratio of 10.70 is amongst the best of the industry. MSLE outperforms 82.17% of its industry peers.
Industry RankSector Rank
Current Ratio 10.7
Quick Ratio 10.7
MSLE Yearly Current Assets VS Current LiabilitesMSLE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MSLE Growth Analysis

3.1 Past

  • MSLE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 4.31% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.3%
EPS Next 2Y2.54%
EPS Next 3Y4.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MSLE Yearly Revenue VS EstimatesMSLE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2028 2M 4M 6M
MSLE Yearly EPS VS EstimatesMSLE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. MSLE Valuation Analysis

4.1 Price/Earnings Ratio

  • MSLE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MSLE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MSLE Price Earnings VS Forward Price EarningsMSLE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MSLE Per share dataMSLE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.54%
EPS Next 3Y4.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MSLE Dividend Analysis

5.1 Amount

  • No dividends for MSLE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MSLE Fundamentals: All Metrics, Ratios and Statistics

SATELLOS BIOSCIENCE INC

NASDAQ:MSLE (4/14/2026, 8:27:47 PM)

After market: 7.17 0 (0%)

7.17

-0.19 (-2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-04
Inst Owners6.2%
Inst Owner ChangeN/A
Ins Owners5.62%
Ins Owner ChangeN/A
Market Cap147.92M
Revenue(TTM)N/A
Net Income(TTM)-21.93M
Analysts84.44
Price Target19.95 (178.24%)
Short Float %0.36%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.58%
Min EPS beat(2)-0.49%
Max EPS beat(2)17.65%
EPS beat(4)2
Avg EPS beat(4)2.4%
Min EPS beat(4)-29.12%
Max EPS beat(4)21.57%
EPS beat(8)4
Avg EPS beat(8)-49.1%
EPS beat(12)6
Avg EPS beat(12)-32.27%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.03%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.35
P/tB 4.35
EV/EBITDA N/A
EPS(TTM)-2.14
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.46%
ROE -64.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.56%
ROA(5y)-132.25%
ROE(3y)-143.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 211401%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.7
Quick Ratio 10.7
Altman-Z 22.74
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146407%
Cap/Depr(5y)87845.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.47%
EPS Next Y12.3%
EPS Next 2Y2.54%
EPS Next 3Y4.31%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.23%
OCF growth 3YN/A
OCF growth 5YN/A

SATELLOS BIOSCIENCE INC / MSLE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SATELLOS BIOSCIENCE INC (MSLE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MSLE.


Can you provide the valuation status for SATELLOS BIOSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to SATELLOS BIOSCIENCE INC (MSLE). This can be considered as Overvalued.


What is the profitability of MSLE stock?

SATELLOS BIOSCIENCE INC (MSLE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MSLE stock?

The Earnings per Share (EPS) of SATELLOS BIOSCIENCE INC (MSLE) is expected to grow by 12.3% in the next year.